Kodiak Sciences reports Q3 EPS (95c) with items, consensus ($1.21)

Q3 net loss included non-cash stock-based compensation of $13.9M, as compared to $26.2M for the quarter ended September 30, 2022. Kodiak ended the Q3 with $345.7M of cash and cash equivalents.”We have three retinal disease prospects in our pipeline: two molecules built with our antibody biopolymer conjugate platform tarcocimab ABC, an anti-VEGF bioconjugate, KSI-501 ABC, a bispecific anti-IL-6 and anti-VEGF bioconjugate, as well as KSI-501 P, a bispecific anti-IL-6 and anti-VEGF protein which is not part of the ABC Platform. We believe this pipeline of three promising retina candidates, combined with our learnings from running six tarcocimab phase 3 pivotal studies, positions the Company well for the future,” said Victor Perlroth, CEO of Kodiak.